Xizhi Chan

Wondered

Business EN ↓ 4 episodes

This podcast series investigates the origins and evolution of biotech innovators. We provide a multi-dimensional analysis of how laboratory uncertainty is transformed into life-saving medicine and forged into a durable, world-changing business, with deep-dive into: - R&D: Tracing the journey from science to Phase III clinical trials. - Finance: Navigating capital structures, financing, and long-term value creation. - Regulation: Mastering FDA and global market authorization strategies. - Leadership: The corporate culture, decision-making, and endurance.

Author

Xizhi Chan

Episodes

ROIvant | PART I: Inside the Decentralized Machine That Disrupted the Biopharma Industry 07.07.2026 37:41

Big Pharma often shelves good drugs. Not because the science failed but because priorities shifted, executives left, or a molecule didn't fit this quarter's strategy. A 28 years old biotech investor at QVT Financial noticed this pattern. In 2014, he founded Roivant Sciences, a company built entirely around exploiting that inefficiency. The name said it all: ROI-vant. Return on Investment. In this...

Inside Abivax (ABVX): The Biotech Stock That Surged 1800% on an IBD Miracle Drug (Obefazimod) 16.06.2026 32:09

How does a failed HIV pill transform into a $10 billion immunology biotech empire, only to see its stock crash on the exact day it releases best-in-class clinical data? In this deep-dive documentary episode, we unpack the wild, 1,800% surging ride of Abivax (NASDAQ: ABVX), and explore the incredible origin story of Obefazimod, a first-in-class small molecule that was abandoned as an antiviral but...

A 35-Year Shell Game: How a Bulgarian Plant Extract Hijacked a 90s Ultrasound Company to Cure Vaping? 26.05.2026 38:25

What does a failed 1990s medical imaging company have to do with the modern vaping epidemic? Everything. In this episode, we trace the incredible 35-year corporate evolution of Achieve Life Sciences (ACHV). We uncover how two biotech veterans orchestrated a $2 million arbitrage play, took over a public shell via a reverse merger, and positioned a 50-year-old Eastern European smoking pill to comple...

How Revolution Medicines Drugged the Undruggable KRAS | Pancreatic Cancer Breakthrough 05.05.2026 53:03

How did Revolution Medicines conquer the "undruggable" KRAS protein? This episode deconstructs the rise of Revolution Medicines (RVMD), a biotech company that paired contrarian science with elite financial engineering to shatter a 40-year oncology stalemate. Time | Topic 02:33 | Why was the KRAS protein considered undruggable for 40 years? 08:18 | How did Revolution Medicines pivot from anti-funga...